Tag: Cancer Drugs

I-Mab Biopharma and Junshi Biosciences Announce Collaboration Agreement

I-Mab Biopharma (I-Mab), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in...

Russian Researchers to Develop AIDS Treatment

Researchers from South Ural State University and the N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences are studying polysulphur-nitrogen heterocycles – organic compounds which ...

WHO Urged Countries to Eliminate Cervical Cancer by 2030

who
World Health Organization urged countries in its South-East Asia Region to accelerate efforts to eliminate cervical cancer by 2030. “Countries need to expand vaccination, screening, detection and tre...

EC Approved LONSURF® as Monotherapy for Treatment of Metastatic Gastric Cancer

Servier and its partner Taiho Pharmaceutical Co., Ltd announced that the European Commission (EC) has approved the use of LONSURF® (trifluridine/tipiracil) as monotherapy for the treatment of adult pa...

EU Approved Roche’s Tecentric plus Chemotherapy for Treatment of ES-SCLC

Roche announced that the European Commission has approved and granted marketing authorisation for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial...

Novartis Announced Positive Results for Ofatumumab Clinical Trials

Novartis, a global leader in neuroscience, announced positive results for ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies. In both head-to-head studies, ofatumumab demonstrated su...

Roche Announced Expanded Use of VENTANA PD-L1 Assay in Triple-Negative Breast Cancer

roche
Roche announced the expanded use of the VENTANA PD-L1 (SP142) Assay in triple-negative breast cancer (TNBC) for patients living in CE (Conformité Européenne) markets where the Roche cancer immunothera...

Immatics Biotechnologies and Celgene Signed Collaboration Deal Worth $1.59bn

Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers. Based in Germany...

Delhi High Court Revoked the Patent on Novartis’ Ceritinib

novartis
A key cancer drug is set to get cheaper in India with the Delhi High Court revoking the patent on Swiss pharma major Novartis’ ceritinib, marketed as Zykadia. The Court suspended the earlier interi...

GSK Announce Primary Objective in Belantamab Mafodotin Multiple Myeloma Trial

gsk
GlaxoSmithKline’s (GSK) immuno-conjugate belantamab mafodotin (GSK2857916) has achieved its primary objective in the multiple myeloma trial. The company has reported positive headline results f...

AstraZeneca Announced Final Results from Global Trial of Imfinzi

astrazeneca
AstraZeneca announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimuma...

GlobalData: Late-Stage Prostate Cancer Pipeline Holds Promise for Future

Although options for prostate cancer have historically been limited, the late-stage prostate cancer pipeline holds promise for the future of this second most common cancer among men, according to Glob...

AstraZeneca Announced Positive Results from Phase III Trial of Tagrisso

astrazeneca
AstraZeneca announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patient...

FDA Granted Breakthrough Therapy Designation for Bempegaldesleukin

Nektar Therapeutics and Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-2...

AstraZeneca and MSD’s Announced Positive Results from the Phase III Trial of Lynparza

preclinical-research
AstraZeneca and MSD Inc., Kenilworth, N.J., US announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) w...

Aquinox and Neoleukin Announced Merger Agreement

Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc., a privately-held biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announc...